FDA Grants Priority Review to BeOne’s Brukinsa Combination
The FDA granted priority review to BeOne’s Brukinsa combination for first-line mantle cell lymphoma.
Related stories
UK Opens Public-Interest Investigation Into Sky-ITV Media Deal
The U.K. government announced a public-interest investigation into Sky’s planned takeover of ITV’s media arm. The available report says Culture Secretary Lisa Nandy will intervene;
L impact | REGULATION | Nov 04, 2026, 02:54 PM UTC
Novogene Sues Trump Administration Over US Listing Decision
A court document says Novogene is suing the Trump administration over the US decision to add it to a list of companies believed to support China's military.
L impact | REGULATION | Nov 04, 2026, 02:43 PM UTC
Westinghouse Poland Subsidiary President Detained in Anti-Fraud Operation
The president of a Westinghouse subsidiary in Poland was detained in an anti-fraud operation.
M impact | REGULATION | Nov 04, 2026, 02:38 PM UTC
EU Lawmakers Back Weaker 2035 Car Emissions Target
A European Parliament committee voted to weaken proposed 2035 car emissions targets, easing the planned requirement that automakers sell only zero-emission vehicles from that date.
M impact | REGULATION | Nov 04, 2026, 02:38 PM UTC
Argentina Bans Endotracheal Suction System, Disposable Gowns Over Falsified Labels
Argentina’s ANMAT banned an endotracheal suction system and disposable gowns nationwide over falsified labels.
L impact | REGULATION | Nov 04, 2026, 02:34 PM UTC
Ruling Requires Single Resolution Board to Repay Part of ABN AMRO Receivable
L impact | REGULATION | Nov 04, 2026, 02:21 PM UTC